Abstract
We present two natalizumab-treated multiple sclerosis patients who developed glioblastoma multiforme (GBM) with variable outcomes. One patient had an isocitrate dehydrogenase (IDH)-wildtype GBM with aggressive behavior, who declined treatment and died 13 weeks after symptoms onset. The other patient underwent resection of an IDH-mutant secondary GBM that arose from a previously diagnosed grade II astrocytoma. He is still alive 5 years after the diagnosis of GBM. JC virus was not detected in either case. Whether natalizumab played a role in the development of GBM in those patients deserves further investigation.
Original language | English (US) |
---|---|
Pages (from-to) | 512-516 |
Number of pages | 5 |
Journal | Annals of clinical and translational neurology |
Volume | 4 |
Issue number | 7 |
DOIs | |
State | Published - Jul 1 2017 |
ASJC Scopus subject areas
- Neuroscience(all)
- Clinical Neurology